Diagnostic Tests

Diagnostic tests | 3/24/2020

PCR, serological, CRISPR: the diagnostic tests Most testing for COVID-19 is currently done on viral genetic material from nose and throat swabs , using a workhorse tool of molecular biology called reverse transcription polymerase chain reaction (RT-PCR). The next big goal is to develop a serological test — one that can detect antibodies in someone who has already recovered. Prominent CRISPR researchers are also working on using the gene-editing …

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report. This report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and …

Follow Diagnostic Tests:    

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… report overview please e-mail Sara Peerun on [email protected] Related reports: Global Genomics Market Report 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… a twin pregnancy. About Myriad Genetics Myriad Genetics Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and …

Polymerase Chain Reaction (PCR) Market - Global Forecast to 2025: Market is Expected to Reach $12.9 Billion - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… Early Detection Of Disease Increasing Demand For PCR In Genetic And Molecular Testing High Prevalence Of Infectious Diseases Increasing Qpcr Based Food Safety Testing Expiry Of Key Players PCR Patents Growing Demand For Rapid Diagnostic Tests Increasing Use Of Companion Diagnostics Technological Advances Restraints and Threats High Cost Of Commercial PCR Assays In Clinical Diagnostics Lack Of Awareness And Requirement Of Skilled Labor Development Of Alternate Technologies Stringent Regulatory Framework …

NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte | BioSpace | 12/4/2019

… in cash and Veracyte stock, plus up to $10 million in cash upon satisfaction of future potential milestones. Under the terms of the agreement, Veracyte has obtained exclusive global rights to develop and commercialize diagnostic tests on NanoString’s nCounter® FLEX system. Veracyte plans to expand the portfolio of nCounter-based diagnostic products using its own proprietary tests. Veracyte has also obtained the rights to the NanoString 510(k)-cleared Prosigna …

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… totaling nearly $10 million focused on developing blood and ocular biomarkers. “Our scientific and business due diligence teams chose these awards based on their promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,” said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. “These awards represent a true collaboration among renown clinicians, who are directly involved …

Alzheimer’s Drug Discovery Foundation’s Diagnostic | 12/4/2019

… consortium, with investments totaling nearly $10 million focused on developing blood and ocular biomarkers. «Our scientific review teams chose these awards based on their promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,» said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. «These awards represent a true collaboration among renown clinicians, who are directly involved …

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2024 - Therapeutics by HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors and Hormone Receptors | PR Newswire | 12/4/2019

… trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report. This report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and …

Global Polymerase Chain Reaction (PCR) Market 2019-2025: Increasing Demand for PCR in Genetic and Molecular Testing | PR Newswire | 12/4/2019

… Early Detection Of Disease Increasing Demand For PCR In Genetic And Molecular Testing High Prevalence Of Infectious Diseases Increasing Qpcr Based Food Safety Testing Expiry Of Key Players PCR Patents Growing Demand For Rapid Diagnostic Tests Increasing Use Of Companion Diagnostics Technological Advances Restraints and Threats High Cost Of Commercial PCR Assays In Clinical Diagnostics Lack Of Awareness And Requirement Of Skilled Labor Development Of Alternate Technologies Stringent Regulatory Framework …

(USA-CA-Remote / Field) Medical Science Liaison, Transplant Diagnostics | 12/4/2019

… for monitoring transplant recipients for organ rejection. The MSL will be familiar with current protocols and best practices of post-transplant patient management and use their expertise to educate the Customer on how these diagnostic tests are useful in clinical evaluation of patient care. Responsibilities include the development and maintenance of internal and external customer relationships in assigned geographic areas, maintaining a high level of customer service, and demonstrating accountability …

HSA Bank Report Shows Consumers are Not Saving for Healthcare | PR Newswire | 12/4/2019

… healthcare, compared to consumers enrolled in other plan types, like PPOs (29%) and HMOs (25%). The breakout report also shows consumers are not reviewing costs prior to receiving routine medical services like doctors’ visits, diagnostic tests and lab fees—common services consumers struggle to pay. In fact, only half of Americans consider the cost before receiving services with 26% listing “frequently” and 22% listing “occasionally.” “Ultimately, consumers can become better …

Global Hematologic Malignancies Testing Market 2019-2025: Increasing Adoption of Inorganic Growth Strategies in the Market | PR Newswire | 12/4/2019

… are their contributions? What is the growth potential of each major hematologic malignancies testing solution provider? Key Topics Covered: Executive Summary 1 Market Overview 1.1 Introduction 1.2 Historical Perspective 1.3 Types of Hematologic Malignancy Diagnostic Tests 1.4 Global Footprint 1.5 Trends and Future Potential 2 Market Dynamics 2.1 Market Drivers 2.1.1 Rising Incidence of Hematologic Malignancies 2.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market 2.1.3 Favorable Reimbursement Scenario …

Here’s Why Qiagen Skyrocketed Over 43% in November | The Motley Fool | 12/4/2019

… Motley Fool since 2007. Follow @BiologyFool What happened Shares of Q iagen ( NYSE:QGEN ) jumped 43.6% in November, according to data provided by S&P Global Market Intelligence , after the maker of scientific and diagnostic tests said that it was considering a potential sale of the company. So what Bloomberg initially reported that Thermo Fisher Scientific ( NYSE:TMO ) was looking to acquire Qiagen, although it cited unnamed sources, and the …

Hepatitis Diagnostic Test Market Anticipated to Achieve Profitable Growth by 2025 | Market Research Report | 12/4/2019

Hepatitis Diagnostic Test Market Size, Share & Trends Analysis Report, By Diagnostic Tests (Liver Function, Immunoassays & Nucleic Acid Assays, Imaging, Liver Biopsy), And Segment Forecasts, 2018 - 2025 The global hepatitis diagnostics market is expected to reach USD 6.9 billion by 2025, according to a new report by Grand View Research, Inc. In the past decade, the burden of hepatitis A, B & C has significantly increased compared to that of type D …

Ranoli facility to manufacture American created IVDs | 12/4/2019

… vitro diagnostics (IVDs) from their facility in Ranoli. The joint venture CoSara Diagnostics Pvt Ltd has received the clearance, said the molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests . The Saragene™ tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) meet the requirements of the Central Drug Standard Control Organization (CDSCO) Medical Device Rules (MDR) 2017, File no. 29 …

100 hospitals and health systems with great orthopedic programs | 2019 | Becker’s Hospital Review | 12/4/2019

… N.C.). Wake Forest Baptist Medical Center is home to one of the world’s only microangiology labs, enabling its orthopedic specialists to find the root causes of chronic hand, shoulder and elbow pain using advanced diagnostic tests . Through the hospital’s Wake Forest Innovations division, orthopedic surgeons are pioneering new treatments with funding from the Department of Defense, the Orthopaedic Research and Education Foundation, and the National Institutes of Health. Wake Forest …

It Takes a “Surgeon” to Cut a Building’s Emissions | 12/4/2019

… identify optimization measures. THE DIAGNOSIS Before conducting a procedure, a surgeon reviews the patient’s medical history, conducts a physical examination, and learns about the patient’s habits (sleep, diet, exercise, etc.). Then, the surgeon evaluates diagnostic tests , such as blood tests, MRIs, and X-rays. Having examined these factors, the physician will use their education and experience to determine the best procedure, and considers the viability of surgery. Building owners and …

Co-Diagnostics JV CoSara Receives Indian Regulatory Approval for Five Diagnostic Assays | Business Wire | 12/3/2019

SALT LAKE CITY- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests , announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), their joint venture for manufacturing, has obtained regulatory clearance for five tests to be manufactured and sold as in vitro diagnostics (“IVDs”) from their facility in Ranoli, India. The Saragene™ tests for Mycobacterium …

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Globe Newswire | 12/3/2019

… extended endocrine therapy. About Myriad Genetics Myriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and …

Molecular Diagnostics

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen … worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major …

Food and Drug Administration

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… this report. This report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available … America Chapter 9 Regulatory Scenario Regulatory Challenges North America U.S. Food and Drug Administration (FDA) Europe Asia-Pacific Japan China South America Brazil Chapter 10 Patent Review/ New Developments Patent Review Companion Diagnostics Patent Expiration …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… British Heart Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Medicare

Health Care Reform Articles - December 3, 2019 | 12/4/2019

We can afford Medicare for All… … and it could even deliver a huge pay raise to the middle class. By EMMANUEL SAEZ and GABRIEL ZUCMAN - Politico - November 25, 2019 The current debate over “Medicare for … Or they can go without care, leaving prescriptions unfilled, skipping diagnostic tests that were ordered by their doctor, hoping that everything will be OK. Advertisement Meanwhile, the cost of care keeps going up, faster than …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Association (AHA) Association for Molecular Pathology (AMP) [US] British Heart Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Biotech

Health Care Reform Articles - December 3, 2019 | 12/4/2019

… expanded at breakneck speed, signing up the influential American Hospital Association and some of the nation’s largest individual hospital systems; biotech trade group BIO; the health care executive roundtable Healthcare Leadership Council; and a series … Or they can go without care, leaving prescriptions unfilled, skipping diagnostic tests that were ordered by their doctor, hoping that everything will be OK. Advertisement Meanwhile, the cost of care keeps going up, faster than …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Cleveland HeartLab Clinigene International Comprehensive Biomarker Center (formerly Febit) Covance Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Precision Medicine

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online … worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major …

Genomics

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Biomarkers • Efficacy Biomarkers • Validation Biomarkers • This report also breaks down the revenue forecast for the global biomarkers market by Discipline: • Genomics • Proteomics • Bioinformatics • Other • This report also breaks down the revenue forecast for the global … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

The Missing Link in Fighting Antibiotic Resistance | 12/4/2019

… data-driven solutions to address antibiotic resistance. These databases are built using pathogen and antibiotic-resistant gene information from rapid diagnostic tests collected at hospitals, clinics and facilities around the world on an ongoing basis … can occur. Companies at the forefront of the technology and genomics industries, however, are already shaking things up with pilot programs supported by major hospital systems and even state governments. In the fight against antibiotic …

Companion Diagnostics

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report. This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors …

Does This Provide a Reason to Sell Myriad Genetics, Inc. (MYGN)? The Stock Has Formed Multiple Bottom Pattern | Finance Recorder | 12/4/2019

… Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $1.84 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and …

Clinical Diagnostics

Polymerase Chain Reaction (PCR) Market - Global Forecast to 2025: Market is Expected to Reach $12.9 Billion - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… diagnostic tests. However, factors like the high cost of commercial PCR assays in clinical diagnostics, lack of awareness and requirement of skilled labor, development of alternate technologies and stringent regulatory framework are hampering the market. By Technique, the PCR market is segmented into standard PCR, real-time PCR, reverse transcriptase PCR, digital PCR, assembly PCR, multiplex PCR, Hot start PCR, and others. Others include nested PCR, Inverse PCR, Immune PCR …

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Globe Newswire | 12/4/2019

… State Conditional Approval Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb Icon Acquires MolecularMD Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling … Genetics/Myriad RBM Nanostring Natera Neogenomics New Oncology Oncocyte Ortho Clinical Diagnostics Perkin Elmer Personal Genome Diagnostics Pfizer Promega Protagen Diagnostics Qiagen Quanterix Rarecells SAS Roche Diagnostics Siemens Silicon Biosystems SkylineDx SRI International Sysmex Thermo …

Cancer Diagnostics

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report. This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… overview please e-mail Sara Peerun on [email protected] Related reports: Global Genomics Market Report 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Cancer Diagnostics

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report. This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… overview please e-mail Sara Peerun on [email protected] Related reports: Global Genomics Market Report 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Abbott Laboratories

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… this report. This report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available … Profile descriptions of the key market leaders, including AbbVie Inc., Abbott Laboratories, Dako, Eli Lilly and Co., Nanostring Technologies, Pfizer Inc., Puma Biotechnology Inc., and Sanofi S.A. Key Topics Covered: Chapter 1 Introduction Study Goals …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Thermo Fisher

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Polymerase Chain Reaction (PCR) Market - Global Forecast to 2025: Market is Expected to Reach $12.9 Billion - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… the field of companion diagnostics using PCR, increasing qPCR based food safety testing, technological advancements and growing demand for rapid diagnostic tests. However, factors like the high cost of commercial PCR assays in clinical diagnostics … Healthcare) Merck Kgaa Promega Corporation Qiagen N.V. Takara Bio, Inc. Thermo Fisher Scientific, Inc. For more information about this report visit https://www.researchandmarkets.com/r/xnbnk0 …

Qiagen

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… plc • Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Global Hematologic Malignancies Testing Market to 2025: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… testing market. Key Topics Covered: Executive Summary 1 Market Overview 1.1 Introduction 1.2 Historical Perspective 1.3 Types of Hematologic Malignancy Diagnostic Tests 1.4 Global Footprint 1.5 Trends and Future Potential 2 Market Dynamics 2.1 Market … Rad Laboratories, Inc. Sysmex Corporation ASURAGEN, INC. Cancer Genetics Inc. QIAGEN N.V. ArcherDX, Inc. Adaptive Biotechnologies ICON plc Quest Diagnostics Incorporated ARUP Laboratories Invivoscribe, Inc. NeoGenomics Laboratories, Inc. For more information about this report visit …

Siemens

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Inc Randox Laboratories Randox Laboratories Roche SABiosciences (now part of QIAGEN) Sandor Proteomic Sanger Institute Sanofi Santaris Pharma Servier Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Globe Newswire | 12/4/2019

… State Conditional Approval Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb Icon Acquires MolecularMD Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling … Pfizer Promega Protagen Diagnostics Qiagen Quanterix Rarecells SAS Roche Diagnostics Siemens Silicon Biosystems SkylineDx SRI International Sysmex Thermo Fisher Trovagene Vortex Biosciences 6. The Global Market for MDx Cancer 6.1 MDx Cancer - Global Market Overview …

Quidel

Quidel Co. (NASDAQ:QDEL) Expected to Announce Earnings of $0.78 Per Share - Transcript Daily | 12/4/2019

Wall Street analysts expect Quidel Co. (NASDAQ:QDEL) to report earnings of $0.78 per share for the current fiscal quarter, according to Zacks . Four analysts have issued estimates for Quidel’s earnings, with estimates ranging from $0.74 to $0.87. Quidel reported earnings per share of $0.80 in the same quarter last year, which suggests a negative year over year growth rate of 2.5%. The company is expected to announce its next …

Thermo Fisher Scientific

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Polymerase Chain Reaction (PCR) Market - Global Forecast to 2025: Market is Expected to Reach $12.9 Billion - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… the field of companion diagnostics using PCR, increasing qPCR based food safety testing, technological advancements and growing demand for rapid diagnostic tests. However, factors like the high cost of commercial PCR assays in clinical diagnostics … Healthcare) Merck Kgaa Promega Corporation Qiagen N.V. Takara Bio, Inc. Thermo Fisher Scientific, Inc. For more information about this report visit https://www.researchandmarkets.com/r/xnbnk0 …

Quest Diagnostics

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Global Hematologic Malignancies Testing Market to 2025: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… testing market. Key Topics Covered: Executive Summary 1 Market Overview 1.1 Introduction 1.2 Historical Perspective 1.3 Types of Hematologic Malignancy Diagnostic Tests 1.4 Global Footprint 1.5 Trends and Future Potential 2 Market Dynamics 2.1 Market … Genetics Inc. QIAGEN N.V. ArcherDX, Inc. Adaptive Biotechnologies ICON plc Quest Diagnostics Incorporated ARUP Laboratories Invivoscribe, Inc. NeoGenomics Laboratories, Inc. For more information about this report visit https://www.researchandmarkets.com/r/polq31 …

Merck

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Polymerase Chain Reaction (PCR) Market - Global Forecast to 2025: Market is Expected to Reach $12.9 Billion - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… the field of companion diagnostics using PCR, increasing qPCR based food safety testing, technological advancements and growing demand for rapid diagnostic tests. However, factors like the high cost of commercial PCR assays in clinical diagnostics … La Roche Ltd (Roche Diagnostics) General Electric Company (Ge Healthcare) Merck Kgaa Promega Corporation Qiagen N.V. Takara Bio, Inc. Thermo Fisher Scientific, Inc. For more information about this report visit https://www.researchandmarkets.com/r/xnbnk0 …

GeneSight

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Markets Insider | Business Insider | 12/4/2019

… company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Genomic Health

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… biomarker technology providers and biomarker diagnostic developers : • AB SCIEX • Agilent • Axela Inc • Caprion Proteomics • Charles River Laboratories • Critical Diagnostics • Epigenomics • Genomic Health • ICON plc • Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Globe Newswire | 12/4/2019

… State Conditional Approval Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb Icon Acquires MolecularMD Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling … Sciences Exosome Diagnostics Fluidigm Corp Fluxion Biosciences Foundation Medicine Freenome Genomic Health GenomOncology GRAIL Guardant Health HalioDx Horizon Discovery HTG Molecular Diagnostics iCellate Illumina Incell Dx Inivata Integrated Diagnostics Invivoscribe Leica Biosystems Luminex MDx Health …

Omni Capital

Age-related macular degeneration treatment at Spire Liverpool Hospital | Spire Healthcare | 12/3/2019

… of what’s included and excluded in your fixed price when paying for yourself. Finance options are available through our partner Omni Capital Retail Finance Ltd, 10 Norwich Street, London, EC4A 1BD. Who will do it … have. We will also discuss with you whether any further diagnostic tests, such as scans or blood tests, are needed. Any additional costs will be discussed before further tests are carried out. Preparing for your …

Age-related macular degeneration treatment at Spire Little Aston Hospital | Spire Healthcare | 12/3/2019

… of what’s included and excluded in your fixed price when paying for yourself. Finance options are available through our partner Omni Capital Retail Finance Ltd, 10 Norwich Street, London, EC4A 1BD. Who will do it … have. We will also discuss with you whether any further diagnostic tests, such as scans or blood tests, are needed. Any additional costs will be discussed before further tests are carried out. Preparing for your …

F-Prime Capital

Temasek leads $220m round for Indian online pharma startup - Nikkei Asian Review | 11/29/2019

F-Prime Capital Fundamentum and San Francisco-based hedge fund Think Investments. BVP also participated in that round. PharmEasy connects patients to local pharmacies and diagnostic centers through an integrated online platform, making healthcare accessible and affordable across India via quick doorstep deliveries and savings on their healthcare needs. It also provides services including home diagnostic tests, medicine dosage reminders and an automated medicine refill subscription. “We deliver medicines to …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service … Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma Genesis Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology …

Goldman Sachs

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service … Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard University Helmholtz Zentrum Mnchen Hercules Capital Histalim HuaKong Equity Investment …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service … Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard University Helmholtz Zentrum Mnchen Hercules Capital Histalim HuaKong Equity Investment …

Domain Associates

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service … Creative Biogene CureDuchenne Dana-Farber Cancer Institute Dharmacon Dicerna Pharmaceuticals Domain Associates EcoR1 Capital Eli Lilly Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service … Creative Biogene CureDuchenne Dana-Farber Cancer Institute Dharmacon Dicerna Pharmaceuticals Domain Associates EcoR1 Capital Eli Lilly Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma …

HealthCare Ventures

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… 15.4.5.3. Lung Cancer 15.4.5.4. Colorectal Cancer 15.4.5.5. Gastric Cancer 15.4.5.6. Hematological Cancer 15.5. miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service Providers 16.2.1. Analysis by Type of Service Provider 16.2.2. Analysis by Location of Service Provider 16.2.3. Analysis by Type of RNAi Molecule …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… 15.4.5.3. Lung Cancer 15.4.5.4. Colorectal Cancer 15.4.5.5. Gastric Cancer 15.4.5.6. Hematological Cancer 15.5. miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service Providers 16.2.1. Analysis by Type of Service Provider 16.2.2. Analysis by Location of Service Provider 16.2.3. Analysis by Type of RNAi Molecule …

Jefferies Financial Group

Stock Analysts’ Updated EPS Estimates for November, 21st (CCR, DTG, FEVR, HAS, HD, MAB, MTH, NOVOB, PACD, PNNT) | 11/21/2019

… price target on the stock. Get C&C Group Plc alerts: Dart Group (LON:DTG) was upgraded by analysts at Jefferies Financial Group Inc to a buy rating. The firm currently has GBX 1,570 ($20.51 … Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that …

Investment Analysts’ Recent Ratings Updates for EXACT Sciences (EXAS) | 11/20/2019

… They now have a “buy” rating on the stock. 10/30/2019 – EXACT Sciences had its price target lowered by analysts at Jefferies Financial Group Inc from $138.00 to $120.00. They now have a “buy” rating on … detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT …

GreatPoint Ventures

Truvian Sciences Accelerates Plans With $27.1 Million Series B Financing to Develop an Automated Benchtop Blood Testing System for Rapid Assessment of a Full Suite of Health Tests | PR Newswire | 11/20/2019

… SAN DIEGO , Nov. 20, Truvian Sciences (“Truvian”) today announced the close of a $27.1 million Series B financing — led by GreatPoint Ventures and including DNS Capital and Tao Capital Partners along with existing investor Domain … wellness panel will cover 40 of the most commonly ordered diagnostic tests including a lipid panel, metabolic panel, complete blood cell count, as well as thyroid, liver and kidney functioning tests. Truvian’s system is engineered …

Zacks Equity Research

Hologic’s Aptima Genitalium Assay Gets Clinically Verified | Zacks | 11/12/2019

Hologic’s Aptima Genitalium Assay Gets Clinically Verified Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full … symptomatic and asymptomatic women and men. This is why accurate diagnostic tests, such as the Aptima Mycoplasma genitalium assay, are instrumental in accurately identifying and treating specific bacterial infections. Results showed that for each of …

OraSure Technologies (OSUR) Q3 Earnings Surpass Estimates | Zacks | 11/7/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article OraSure Technologies ( OSUR - Free Report ) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items …

Maxim Group

Navidea Biopharmaceuticals’ (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/9/2019

… Chief Executive Officer Mike Rosol – Chief Medical Officer Erika Gibs – Director of Finance and Administration Conference Call Participants Jason McCarthy – Maxim Group Rick Drew – Private Investor Jed Latkin Good afternoon, and welcome, everyone, to Navidea’s … relate to the effectiveness of the company’s bodily fluid-based diagnostic tests as well as the company’s ability to develop and successfully commercialize such test platforms for early detection of cancer and the diagnosis and …

Interpace Diagnostics Group (NASDAQ:IDXG) Shares Pass Above 200-Day Moving Average of $0.76 | 11/3/2019

… a research note on Thursday, September 26th. They set an “outperform” rating and a $3.00 price target on the stock. Maxim Group set a $2.00 price target on shares of Interpace Diagnostics Group and gave … NASDAQ:IDXG )Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion …

Cambridge Innovation Capital

OBN Awards 2019 - Winners Recognised at Industry Leading Event | PR Newswire | 11/8/2019

… Award , kindly sponsored by Mills & Reeve Winner - Attomarker Develop iPhone connected diagnostic technology to enable rapid and personal access to diagnostic tests conventionally carried out in analytical laboratories. Best Established Biotech Company , kindly sponsored by … Head of Business Development - Oxford Biomedica Robert Tansley - Investment Director - Cambridge Innovation Capital Rebecca Todd - Investment Director - Longwall Venture Partners About OBN OBN is the Membership organisation supporting and bringing together the UK’s emerging life …

OBN Awards 2019 - Winners Recognised at Industry Leading Event | Markets Insider | Business Insider | 11/8/2019

… Award , kindly sponsored by Mills & Reeve Winner - Attomarker Develop iPhone connected diagnostic technology to enable rapid and personal access to diagnostic tests conventionally carried out in analytical laboratories. Best Established Biotech Company , kindly sponsored by … Head of Business Development - Oxford Biomedica Robert Tansley - Investment Director - Cambridge Innovation Capital Rebecca Todd - Investment Director - Longwall Venture Partners About OBN OBN is the Membership organisation supporting and bringing together the UK’s emerging life …

Mayo Clinic

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… of QIAGEN) Isogen Life Science Johnson & Johnson (J&J) KU Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications | Globe Newswire | 12/4/2019

… and Molecular Subtyping Kit sphingotec and Ortho Jointly Offer sphingotest bio-ADM Assay for Clinical Laboratories Globally Agendia and Institute Curie Partners for the Co-validation Study of MammaPrint BluePrint Kit sphingotec and Mayo Clinic Partner to Assess Four Biomarkers EKF’s Procalcitonin Assay Wins FDA Clearance and Validated for Beckman AU Chemistry Analyzers Genomic Health Develops New Prostate Cancer Tests based on Cleveland Diagnostics’ IsoPSA Reagent and SIA Technology Release …

Massachusetts General Hospital

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… US] Hirosaki University Human Proteome Organisation (HUPO) International Cancer Genome Consortium (ICGC) Les entreprises du médicament (LEEM) [ France ] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

ACR and EULAR Release New Classification Criteria for IgG4-Related Disease | 12/4/2019

… this to determine whether a patient should be classified as having IgG4-RD.” Dr. Stone is a professor of medicine for Harvard Medical School and the Edward A. Fox Chair in Medicine at Massachusetts General Hospital. About the American College of Rheumatology The American College of Rheumatology (ACR) is an international medical society representing over 8,500 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel …

UPMC

(USA-PA-Pittsburgh) Clinical Care Manager - Maternity - Southern Allegheny & Washington Counties (RN) | 12/4/2019

UPMC Clinical Care Manager - Maternity - Southern Allegheny & Washington Counties (RN) in Pittsburgh , Pennsylvania Description Are you an experienced OB or Maternity nurse with a familiarity with care management or home health? Do you have an … care services and assist them to schedule required screening or diagnostic tests with their providers. Assist member to schedule a follow up appointment after emergency room visits or hospitalizations. Plan standards and identify trends and …

(USA-PA-Beaver) Clinical Care Manager - Maternity - Beaver, Butler & Lawrence Counties (RN) | 12/4/2019

UPMC Clinical Care Manager - Maternity - Beaver, Butler & Lawrence Counties (RN) in Beaver , Pennsylvania Description Are you an experienced OB or Maternity nurse with a familiarity with care management or home health? Do you have an … care services and assist them to schedule required screening or diagnostic tests with their providers. Assist member to schedule a follow up appointment after emergency room visits or hospitalizations. Plan standards and identify trends and …

Ascension

100 hospitals and health systems with great orthopedic programs | 2019 | Becker’s Hospital Review | 12/4/2019

… also cover athletic events throughout the state. Orthopaedic Hospital of Wisconsin (Glendale). Orthopaedic Hospital of Wisconsin is a member of Ascension Wisconsin and serves patients from across the state. Since being established in 2001 as … causes of chronic hand, shoulder and elbow pain using advanced diagnostic tests. Through the hospital’s Wake Forest Innovations division, orthopedic surgeons are pioneering new treatments with funding from the Department of Defense, the Orthopaedic Research …

Muni Credit News Week of November 18, 2019 | 11/19/2019

ASCENSION CAUGHT UP IN TECH DISPUTE The Department of Health and Human Service’s Office for Civil Rights, the federal agency that enforces HIPAA, would “like to learn more information about this mass collection of individuals … changes to a patient’s care, such as different treatment plans, diagnostic tests or additional physicians, as well as to flag unexpected deviations in the patient’s care. Google has struck similar partnerships with the health systems …

Rush University Medical Center

100 hospitals and health systems with great orthopedic programs | 2019 | Becker’s Hospital Review | 12/4/2019

… Outstanding Patient Excellence Award, Patient Safety Excellence Award and Excellence Awards for total knee, hip and joint replacement from Healthgrades. Rush University Medical Center (Chicago). Rush University Medical Center orthopedic surgeons perform around 3,800 hip … causes of chronic hand, shoulder and elbow pain using advanced diagnostic tests. Through the hospital’s Wake Forest Innovations division, orthopedic surgeons are pioneering new treatments with funding from the Department of Defense, the Orthopaedic Research …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

… experience in clinical psychiatry and neuroscience. Most recently, he served as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of … worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major …

Banner Health

100 hospitals and health systems with great orthopedic programs | 2019 | Becker’s Hospital Review | 12/4/2019

… orthopedic programs in the nation by U.S. News & World Report and supports research and clinical trials for new orthopedic treatments. Banner Health (Phoenix). Banner Health’s orthopedic program spans hospitals in Phoenix, Tucson and Northern Colorado … causes of chronic hand, shoulder and elbow pain using advanced diagnostic tests. Through the hospital’s Wake Forest Innovations division, orthopedic surgeons are pioneering new treatments with funding from the Department of Defense, the Orthopaedic Research …

Physician assistant and Imperial native joins Ogallala Community Hospital - North Platte Telegraph | 11/17/2019

OGALLALA — Banner Health has announced the addition of Erica Ellicott, PA, to Ogallala Community Hospital where she will provide care with an emphasis on full-service health care as a physician assistant. As a physician assistant, or PA, Ellicott is skilled in providing all aspects of health care to patients, according to a press release. Ellicott is highly trained in physical exams, ordering and interpreting diagnostic tests and developing and …

Cleveland Clinic

FDA Watch: Agency Clears the Way for Approval of Blood-Based PSA Test | 12/3/2019

Cleveland Clinic dedicated to developing next-generation diagnostic tests for early cancer detection, announced that it has received FDA breakthrough device for a test that uses a new and more accurate methodology for detecting prostate cancer risk: The so-called IsoPSA test doesn’t simply measure PSA levels but evaluates structural changes to the PSA protein allowing for more accurate differentiation between cancer and non-cancerous conditions; it is also capable …

Calculating the Costs of Clinical Trials | 12/1/2019

… thousands of dollars out of pocket for a specialty tier drug. In The Hill, Mikkael Sekeres, MD, MS, editor-in-chief of ASH Clinical News and director of the Leukemia Program at the Cleveland Clinic, recalled the devastating moment experienced by many patients when, “after devoting themselves to the trial requirements and jeopardizing their own health for the benefit of others, they are faced with the realization that access to …

Intermountain Healthcare

Wellness Wednesday: Treating Cancer Patients Who Are At Risk for Heart Problems | fox13now.com | 12/2/2019

Early cancer detection and improved treatments have allowed many patients with cancer to live longer. However, some patients may be at an increased risk for cardiovascular complications and other medical issues, due to certain cancer treatments. That’s why Intermountain Healthcare has developed a new Cardio-Oncology program. The Intermountain Cardio-Oncology program at Intermountain Medical Center in Murray and LDS Hospital in Salt Lake City was developed to help people …

(USA-UT-Salt Lake City) Pulmonary (PFT) Respiratory Therapist- Eccles Outpatient Clinic (Primary Children’s Hospital) | 11/16/2019

Home View All Jobs ( 2,384,457 ) Job Information Intermountain Healthcare Pulmonary (PFT) Respiratory Therapist- Eccles Outpatient Clinic (Primary Children’s Hospital) in Salt Lake City , Utah Job ID:241354 Details: About Us Being a part of Intermountain Healthcare means joining a world-class team of over 37,500 employees and caregivers while embarking on a career filled with opportunities, strength, innovation, and fulfillment. Our mission is: Helping people live the healthiest lives possible …

Kaiser Permanente

(USA-OR-Portland) LPN - Pain Management (36 Hours) Interstate/Portland | 12/1/2019

Job Information Kaiser Permanente LPN - Pain Management (36 Hours) Interstate/Portland in Portland , Oregon Participate w/the Health Care Team in delivering quality & customer focused care to patients in a manner which reflects KP’s organizational & nursing mission, vision & values. Provides nursing & administrative support to clinicians & other health care team members to offer a variety of health care service to patients. Clinical duties involve both direct (in person) & indirect (via phone …

The Health Economy | 11/27/2019

… each company’s active projects totaling more than $2 billion in value. The University of Maryland Medical System, Virtua Health, and Kaiser Permanente each have planned projects that range in total value from $1.4 to $1.6 … more than threequarters of the population would be covered. Many diagnostic tests could be moved into retail care settings, and researchers have estimated that 14 percent to 27 percent of emergency department visits could be …

One Medical

Co-Diagnostics, Inc. Continues to Execute on International Expansion | 11/26/2019

… Lake City— Co-Diagnostics, Inc. (Nasdaq: CODX) , a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced that in a recent visit to Ghana the Company collaborated with Dare … Ghana, as in other sub-Saharan African countries, the number one medical reason for employees’ absence from work, students’ absence from school and patients’ frequent visits to the hospital is malaria. Dare Labs in collaboration …

Open letter to the UK Home Secretary Priti Patel and Shadow Home Secretary Diane Abbott | Critical Analysis |Axisoflogic.com | 11/25/2019

… Embassy (a foreign jurisdiction); whether the association with Mr Assange could harm their livelihood or draw unwanted attention to them and their families; and discomfort regarding exposing this association when entering the Embassy. One medical practitioner expressed concern to one of the interviewees after the police taking notes of his name and the fact that he was visiting Mr Assange. One medical practitioner wrote that he agreed to produce a …

Cigna

Health Care Reform Articles - December 3, 2019 | 12/4/2019

… slowed the growth of medical costs—for a while. But under the Trump administration, health-care sector mergers (such as Cigna-Express Scripts, CVS-Aetna and Optum-DaVita) have effectively reduced competition and increased pricing … Or they can go without care, leaving prescriptions unfilled, skipping diagnostic tests that were ordered by their doctor, hoping that everything will be OK. Advertisement Meanwhile, the cost of care keeps going up, faster than …

Calculating the Costs of Clinical Trials | 12/1/2019

… standards of care for a particular diagnosis.” 5 Aetna’s website stipulates that “all applicable plan limitations for coverage of out-of-network care will apply to routine care costs in clinical trials.” 6 Cigna’s clinical trial fact sheet notes that routine patient services, such as transplant-related services or select outpatient services, are managed the same way whether they are part of or outside of an approved trial – and are …

UnitedHealthcare

Genomind Bolsters Medicare Reimbursement Initiatives, Obtaining Z-Codes for Genomind Professional PGx Express | 11/7/2019

… requisites for MolDX clinical utility and clinical validity review. This process identifies and establishes coverage and reimbursement policies for molecular diagnostic tests, which would include Genomind Professional PGx Express, as part of Medicare’s Local Coverage … relevant to anxiety and depression, and is currently covered by UnitedHealthcare for certain patients. For both the full and CORE reports, Genomind provides medication-specific results to the clinician team only. In addition to the …

Aetna

Exact Sciences Corp (EXAS) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019

… in 2019: one, powering our partnership with Pfizer, two, enhancing Cologuard; and three, advancing our pipeline of blood-based cancer diagnostic tests.Starting with our first priority, we’re confident that we can capture at least 40 … following the American Cancer Society guidelines update last year, including Aetna, CareFirst and Blue Shield of California. This is encouraging progress and our team is engaging with other payers educating their sales force and developing …

What’s in the Offing for LabCorp’s (LH) Earnings in Q3? | MSN | 10/21/2019

… Aetna, placing LabCorp in-network under all major national plans. Ever since, the company has been registering consistent organic growth on the back of these partnerships. The upside is likely to get reflected in the company’s third-quarter results. Second, the company is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter, backed by the introduction of two new companion diagnostic tests, namely PIK3CA for …

Humana

Humana Releases Update to Facility Observation Services Payment Policy | 10/30/2019

Humana has issued a new claims payment policy for appropriate billing and documentation of facility observation services -specific, clinically appropriate outpatient services provided to help a healthcare professional decide whether a patient needs to be admitted as an inpatient or can be discharged. The policy update outlines the criteria that Humana plans use to determine appropriate billing and documentation of facility observation services. The following policy applies to facility services …

Opko Health (OPK) Q2 2019 Earnings Call Transcript - Nasdaq.com | 8/8/2019

… a result of our wins in the ACO and IPA space and leveraging our recent selection to be part of the preferred lab network with UnitedHealthcare and our new in-network status with Humana. In addition, our sales force are aggressively pursuing leakage opportunities in partnership with our payer partners. In our targeted areas of specific expertise, we have appointed a new leader for women’s health and a new leader …

Health Net

Health tech funding snapshot—Capsule lands $200M, Optum Ventures joins $24M round in Vim and more | FierceHealthcare | 10/4/2019

… to expand its primary care footprint in existing and new markets and enhance docOS, its market-leading primary care platform. Diagnostic tests: Tel Aviv, Israel-based Healthy.io developed a platform to turn a smartphone camera … of Sanofi, the Maryland Momentum Fund, the University of Vermont Health Network and TEDCO. Behavioral health: Ginger , an on-demand behavioral healthcare company, secured $35 million in a series C funding round led by WP …

Philadelphia diagnostics disruptor teams up with Lehigh Valley firm for clinical trial | The Business Journals | 8/22/2019

Senior Reporter, Philadelphia Business Journal Aug 22, 2019, 10:46am EDT A Philadelphia biotechnology company that is out to transform how patients get diagnostic tests has formed a partnership with a Lehigh Valley-based laboratory services provider. Under the collaboration, Group K Diagnostics and Health Network Laboratories of Allentown will work together to make Group K’s technology accessible to HNL patients, Specifically, patients seeking liver-function testing have the opportunity to …

Independent Health

OncoCyte Presents Positive Results from R&D Validation Study of DetermaVu™ at the American Thoracic Society 2019 International Conference | Markets Insider | Business Insider | 5/21/2019

… independent health economics firm, cost on average $14,634 each. In addition, DetermaVu™ can provide great benefit to patients by avoiding invasive biopsies and the complications that arise in up to 24% of those procedures, and deaths that occur in up to 1% of cases. DetermaVu™ is a trademark of OncoCyte Corporation About OncoCyte Corporation OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic …

OncoCyte Corporation (OCX) CEO William Annett on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/15/2019

… forward-looking statements. These factors may include without limitation, risks inherent in the development and/or the commercialization of potential diagnostic tests, uncertainties in the results of clinical trials or regulatory approvals, the capacity of … expensive. According to a study of Medicare data by an independent Health Economics firm, they have an average cost of nearly $15,000. This means that increased screening for early detection without DetermaVu would likely also …

Dwight Egan

Ranoli facility to manufacture American created IVDs | 12/4/2019

… Ltd has received the clearance, said the molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests. The Saragene™ tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human … a multiplexed panel specifically for blood-bank screening. Company CEO Dwight Egan remarked “India is soon to become the largest healthcare market on the planet and the best place for Co-Primer-powered products to …

Co-Diagnostics JV CoSara Receives Indian Regulatory Approval for Five Diagnostic Assays | Business Wire | 12/3/2019

… Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), their joint … more, including a multiplexed panel specifically for blood-bank screening. Dwight Egan, Company CEO, remarked, “India is soon to become the largest healthcare market on the planet and the best place for CoPrimer-powered products …

Bill Gates

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… 2018 with funding commitments totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation … promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,” said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. “These awards …

Alzheimer’s Drug Discovery Foundation’s Diagnostic | 12/4/2019

… 2018 with funding commitments totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation … promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,» said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. «These awards …

MacKenzie Bezos

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal … promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,” said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. “These awards …

Alzheimer’s Drug Discovery Foundation’s Diagnostic | 12/4/2019

… totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal … promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,» said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. «These awards …

Sara Peerun

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-biomarkers … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Visiongain Report Offers Transformative Insights on the $21.3bn Precision Cancer Diagnostic Tests Market | Markets Insider | Business Insider | 8/14/2019

Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 - Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy LONDON , Aug. 14, 2019 /PRNewswire/ – The global … act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-precision-cancer-diagnostic-tests-market-forecasts-2019-2029/ download_sampe_div Report …

Tedros Adhanom Ghebreyesus

More pregnant women and children protected from malaria, but accelerated efforts and funding needed to reinvigorate global response, WHO report shows | 12/4/2019

… and low birth weight – a leading cause of child mortality. “Pregnant women and children are the most vulnerable to malaria, and we cannot make progress without focusing on these two groups,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “We’re seeing encouraging signs, but the burden of suffering and death caused by malaria is unacceptable, because it is largely preventable. The lack of improvement in the number of cases and …

World AIDS Day: 37.9 m people living with HIV globally – WHO | 12/1/2019

… HIV testing, prevention, treatment and care as a core strategy. Reacting to the report, the Director-General of WHO, Dr Tedros Adhanom Ghebreyesus recommended a strategic mix of approaches for testing, including community-based testing … how trained peers or community health workers have delivered rapid diagnostic tests with same-day results, enabling more people to know their HIV status. “Health services are struggling to provide all people with HIV services …

Cameron Reynolds

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia | PR Newswire | 12/3/2019

… other assays in development also demonstrated promising individual assay results with AUCs ranging from 79% to 91%. An interview with Cameron Reynolds Commenting on these results Dr. Jake Micallef , Chief Scientific Officer at Volition said … looking statements relate to the effectiveness of Volition’s blood-based diagnostic tests as well as Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition’s actual …

VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update | PR Newswire | 11/13/2019

… Eastern Time to discuss these results. Conference call details may be found below. An interview with Volition’s Chief Executive Officer, Cameron Reynolds Cameron Reynolds , President and Chief Executive Officer of Volition, upon releasing these results … poor and/or narrow. 20 patent families related to our diagnostic tests (including both human and veterinary medicine applications). 8 patents granted in the United States . 7 patents granted in the European Union. 25 further …

Richard Godfrey

Piramal Pharma Solutions Announces Collaboration With BerGenBio on the Development of FDA Fast Track Designated Leukemia Treatment | PR Newswire | 12/3/2019

… integrated business model. The breadth and scale of our assets and our expertise as a leading CDMO allow us to customize services according to their needs and deliver solutions that benefit the patients.” Richard Godfrey , Chief Executive Officer of BerGenBio , stated that “Outsourcing of development and manufacturing services is a requirement for us, and we were rigorous in our due diligence of potential partners. Piramal Pharma Solutions’ capabilities – especially the …

Melinda Gates

How the neglected AIDS epidemic hits women and girls hardest | 12/2/2019

… is the DREAMs programme , a partnership with the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the Bill and Melinda Gates Foundation, among other funders, to reduce new HIV infections in adolescent girls and … the virus are provided free of charge, but medications and diagnostic tests for illness caused by opportunistic pathogens are not, which drives up deaths from diseases such as tuberculosis and cryptococcal meningitis. Food insecurity has …

Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance | 11/30/2019

… outcomes, including a clinical mass spectrometry-based proteomics assay Lucence Diagnostics MEDx (Suzhou) Translational Medicine Objective: Develop cancer-related companion diagnostic tests for China Dynamic: Tests to be codeveloped for PD-L1 rearrangement to be … being funded via expansion of existing grant from The Bill & Melinda Gates Foundation PredictImmune KSL Biomedical Objective: Commercialize PredictImmune PredictSURE inflammatory bowel disease test in North America Dynamic: Under exclusive commercial partnership, KSL to commercialize …

Amit Kumar

Anixa Biosciences Announces Presentation at the 2019 San Antonio Breast Cancer Symposium | PR Newswire | 12/2/2019

… breast cancer (BCa) Authors: George A. Dominguez , Ph.D.; John Roop ; Alex Polo ; Anthony J. Campisi ; Dmitry I. Gabrilovich , MD, Ph.D.; Amit Kumar , Ph.D. Poster Session and Number: Session 5, P5-01-16 Location: Henry B. Gonzalez Convention … of Cchek™ makes it a platform from which multiple cancer diagnostic tests may be developed. The first such test, a prostate cancer confirmation test, is slated for commercial launch by the end of 2019. About …

Nihon Kohden

Neurodiagnostics Market To Reach USD 25.14 Billion By 2026 | Reports And Data | Globe Newswire | 11/26/2019

… a CAGR of 7.8%. The study involves the analysis of the market for Neurodiagnostics, which consists of a series of diagnostic tests and medical procedures conducted to identify the malfunctions of the central nervous system … key players are catering to these dynamic needs. For instance, Nihon Kohden launched its airEEG WEE-1200 wireless system which helped in the continuous and comprehensive term monitoring of diseases like Epilepsy Asia-Pacific regional …